NexGenix Pharmaceuticals, founded in 2003, is a biotechnology startup with a focus on developing the "next generation" of targeted therapies for cancer and diseases of the nervous system such as glioblastoma, neurodegenerative diseases, neurofibromatosis, and autism-spectrum disorders. The company has secured a $3.9M Series B investment on 16 July 2007. NexGenix possesses a robust structural chemistry platform in resorcylic macrolides, highly potent inhibitors of the chaperone, heat shock protein 90 (Hsp90). Its innovative Hsp90 inhibitors, based on the highly potent compound radicicol, display the potential to be best-in-class drugs for diseases characterized by misregulation of protein homeostasis, including cancer, neurofibromatosis, ALS, and Parkinson's disease. The company has established a strong network of scientific advisors and collaborators specializing in protein folding, kinase signaling, oncogenesis, and neurodegenerative diseases. Additionally, NexGenix holds a growing portfolio of intellectual property covering its key efforts.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $3.90M | - | 16 Jul 2007 | |
| Series B | Unknown | 1 |
|
07 Sep 2005 |
No recent news or press coverage available for NexGenix Pharmaceuticals.
We care about your data, and we'd love to use cookies make your experience better.